Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review

References

• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030–1043. doi:10.1016/S0140-6736(08)60457-2
   PubMed Web of Science ®Google Scholar
• Silverman LB, Stevenson KE, O’Brien JE, et al. Long-term results of Dana-Farber cancer institute ALL consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia. 2010;24(2):320–334. doi:10.1038/leu.2009.253
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood. 2001;97(5):1211–1218. doi:10.1182/blood.v97.5.1211
   PubMed Web of Science ®Google Scholar
• Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of total therapy study XIIIB at St jude children’s research hospital. Blood. 2004;104(9):2690–2696. doi:10.1182/blood-2004-04-1616
   Web of Science ®Google Scholar
• Brown P, Inaba H, Annesley C, et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(1):81–112. doi:10.6004/jnccn.2020.0001
   PubMed Web of Science ®Google Scholar
• Mattano LA, Devidas M, Friedmann AM, et al. Outstanding outcome for children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: results of Children’s Oncology Group (COG) Study AALL0331. Blood. 2014;124(21):793. doi:10.1182/blood.V124.21.793.793
   Web of Science ®Google Scholar
• Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E 3rd, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983;43(11):5601–5607.
   PubMed Web of Science ®Google Scholar
• Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother. 2016;7(2):62–71. doi:10.4103/0976-500X.184769
   PubMed Web of Science ®Google Scholar
• Kawedia JD, Rytting ME. Asparaginase in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014;14(Suppl):S14–S17. doi:10.1016/j.clml.2014.06.017
   Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730–2741. doi:10.1056/NEJMoa0900386
   PubMed Web of Science ®Google Scholar
• Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2010;24(1):1–18. doi:10.1016/j.hoc.2009.11.014
   PubMed Web of Science ®Google Scholar
• Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986;315(11):657–663. doi:10.1056/NEJM198609113151101
   PubMed Web of Science ®Google Scholar
• Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335–342. doi:10.1038/sj.leu.2401310
   PubMed Web of Science ®Google Scholar
• Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group Phase 3 trial. Blood. 2002;99(8):2734–2739. doi:10.1182/blood.v99.8.2734
   PubMed Web of Science ®Google Scholar
• Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161–7167. doi:10.1200/jco.2005.11.411
   PubMed Web of Science ®Google Scholar
• Hefazi M, Litzow MR. Recent advances in the biology and treatment of T cell acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2018;13(4):265–274. doi:10.1007/s11899-018-0455-9
   PubMed Web of Science ®Google Scholar
• Schrappe M, Möricke A, Reiter A, et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr. 2013;225(Suppl S 01):S62–S72. doi:10.1055/s-0033-1337966
   Web of Science ®Google Scholar
• Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children’s Oncology Group study (CCG-1941). Pediatr Blood Cancer. 2006;47(2):141–146. doi:10.1002/pbc.20713
   Web of Science ®Google Scholar
• Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006;1(3):241–254.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children’s Oncology Group. J Clin Oncol. 2020;38(17):1897–1905. doi:10.1200/JCO.19.03024
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Oncaspar (pegaspargase): summary of product characteristics. 2018. Available from: http://www.ema.europa.eu/. Accessed March 15, 2021.
   Google Scholar
• Shire Pharmaceuticals. Oncaspar (pegaspargase): US prescribing information. 2019. Available from: http://www.fda.gov. Accessed March 15, 2021.
   Google Scholar
• Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991–998. doi:10.1634/theoncologist.12-8-991
   PubMed Web of Science ®Google Scholar
• Avramis V, Sencer S, Periclou A, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2002;99:1986–1994. doi:10.1182/blood.V99.6.1986
   PubMed Web of Science ®Google Scholar
• Heo YA, Syed YY, Keam SJ. Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs. 2019;79(7):767–777. doi:10.1007/s40265-019-01120-1
   PubMed Web of Science ®Google Scholar
• Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621–629.
   PubMed Web of Science ®Google Scholar
• Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med. 1963;118(1):99–120. doi:10.1084/jem.118.1.99
   PubMed Web of Science ®Google Scholar
• Schwartz JH, Reeves JY, Broome JD. Two L-asparaginases from E. coli and their action against tumors. Proc Natl Acad Sci U S A. 1966;56(5):1516–1519. doi:10.1073/pnas.56.5.1516
   Web of Science ®Google Scholar
• Boyse EA, Old LJ, Campbell HA, Mashburn LT. Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase. J Exp Med. 1967;125(1):17–31. doi:10.1084/jem.125.1.17
   Web of Science ®Google Scholar
• Meneguetti GP, Santos JHPM, Obreque KMT, et al. Novel site-specific PEGylated L-asparaginase. PLoS One. 2019;14(2):e0211951. doi:10.1371/journal.pone.0211951
   Web of Science ®Google Scholar
• Lebovic R, Pearce N, Lacey L, Xenakis J, Faircloth CB, Thompson P. Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3750 IU. Pediatr Blood Cancer. 2017;64(10):e26555. doi:10.1002/pbc.26555
   Web of Science ®Google Scholar
• van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279–285. doi:10.3324/haematol.2015.137380
   PubMed Web of Science ®Google Scholar
• Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677–1690. doi:10.1016/S1470-2045(15)00363-0
   PubMed Web of Science ®Google Scholar
• Schore RJ, Devidas M, Bleyer A, et al. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children’s Oncology Group AALL07P4. Leuk Lymphoma. 2019;60(7):1740–1748. doi:10.1080/10428194.2018.1542146
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Blonquist TM, Supko JG, et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: results of DFCI 11-001. J Clin Oncol. 2019;37(15_suppl):10006. doi:10.1200/JCO.2019.37.15_suppl.10006
   Web of Science ®Google Scholar
• Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367–393. doi:10.2165/00003088-200544040-00003
   PubMed Web of Science ®Google Scholar
• Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7):1351–1353. doi:10.1182/blood-2009-09-245951
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children’s Oncology Group Study AALL07P4. J Clin Oncol. 2014;32(34):3874–3882. doi:10.1200/JCO.2014.55.5763
   PubMed Web of Science ®Google Scholar
• Lew G. Space for calaspargase? A new asparaginase for acute lymphoblastic leukemia. Clin Cancer Res. 2020;26(2):325–327. doi:10.1158/1078-0432.CCR-19-2975
   Web of Science ®Google Scholar
• Pui C-H, Liu Y, Relling MV. How to solve the problem of hypersensitivity to asparaginase? Pediatr Blood Cancer. 2018;65(3):e26884. doi:10.1002/pbc.26884
   Web of Science ®Google Scholar
• Rau RE, Dreyer Z, Choi MR, et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2018;65(3):e26873. doi:10.1002/pbc.26873
   Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Andrzejewski W, Młynarski W, Jedrychowska-Dańska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007;48(5):931–936. doi:10.1080/10428190701292049
   PubMed Web of Science ®Google Scholar
• Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91(1):24–31.
   PubMed Web of Science ®Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112(5):1646–1654. doi:10.1182/blood-2008-01-130237
   PubMed Web of Science ®Google Scholar
• Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009;113(7):1408–1411. doi:10.1182/blood-2008-06-164863
   PubMed Web of Science ®Google Scholar
• Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012;87(5):472–478. doi:10.1002/ajh.23149
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Beck J, Brandt K, et al. Significant Improvement of outcome in Adolescents and Young adults (AYAs) aged 15-35 years with Acute Lymphoblastic Leukemia (ALL) with a pediatric derived adult ALL protocol; results of 1529 AYAs in 2 consecutive trials of the German Multicenter Study Group For Adult ALL (GMALL). Blood. 2013;122(21):839.
   Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21(5):774–780. doi:10.1200/JCO.2003.02.053
   PubMed Web of Science ®Google Scholar
• de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18(12):2032–2035. doi:10.1038/sj.leu.2403538
   PubMed Web of Science ®Google Scholar
• Testi AM, Attarbaschi A, Valsecchi MG, et al. Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. Eur J Cancer. 2019;122:61–71. doi:10.1016/j.ejca.2019.09.004
   Web of Science ®Google Scholar
• Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018;2018(1):137–145. doi:10.1182/asheducation-2018.1.137
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res. 2004;10(16):5335–5341. doi:10.1158/1078-0432.Ccr-04-0222
   PubMed Web of Science ®Google Scholar
• Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009–2017. doi:10.1016/S0140-6736(10)62002-8
   PubMed Web of Science ®Google Scholar
• Frandsen TL, Heyman M, Abrahamsson J, et al. Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. Eur J Cancer. 2014;50(2):251–259. doi:10.1016/j.ejca.2013.09.027
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17(6):e231–e239. doi:10.1016/S1470-2045(16)30035-3
   PubMed Web of Science ®Google Scholar
• Burke MJ, Devidas M, Maloney K, et al. Severe pegaspargase hypersensitivity reaction rates (grade >/=3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials. Leuk Lymphoma. 2018;59(7):1624–1633. doi:10.1080/10428194.2017.1397658
   PubMed Web of Science ®Google Scholar
• Rathod S, Ramsey M, Relling MV, Finkelman FD, Fernandez CA. Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors FcεRI and FcγRIII. Haematologica. 2019;104(2):319–329. doi:10.3324/haematol.2018.199448
   Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238–249. doi:10.1002/cncr.25489
   PubMed Web of Science ®Google Scholar
• Strullu M, Corradini N, Audrain M, et al. Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2010;51(8):1464–1472. doi:10.3109/10428194.2010.494316
   PubMed Web of Science ®Google Scholar
• Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, Młynarski W. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med. 2009;9(2):113–116. doi:10.1007/s10238-008-0026-9
   PubMed Web of Science ®Google Scholar
• Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000;18(7):1525–1532. doi:10.1200/jco.2000.18.7.1525
   PubMed Web of Science ®Google Scholar
• Müller H-J, Beier R, Löning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol. 2001;114(4):794–799. doi:10.1046/j.1365-2141.2001.03009.x
   PubMed Web of Science ®Google Scholar
• Henriksen LT, Harila-Saari A, Ruud E, et al. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. Pediatr Blood Cancer. 2015;62(3):427–433. doi:10.1002/pbc.25319
   PubMed Web of Science ®Google Scholar
• Hojfeldt SG, Wolthers BO, Tulstrup M, et al. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008. Br J Haematol. 2019;184(3):405–417. doi:10.1111/bjh.15660
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123(13):2026–2033. doi:10.1182/blood-2013-10-534347
   PubMed Web of Science ®Google Scholar
• Kloos RQ, Pieters R, Escherich G, van der Sluis IM. Allergic-like reactions to asparaginase: atypical allergies without asparaginase inactivation. Pediatr Blood Cancer. 2016;63(11):1928–1934. doi:10.1002/pbc.26123
   Web of Science ®Google Scholar
• Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children’s Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33(8):610–616. doi:10.1097/MPH.0b013e31822d4d4e
   PubMed Web of Science ®Google Scholar
• Würthwein G, Lanvers-Kaminsky C, Gerss J, et al. Therapeutic drug monitoring of asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-Asparaginase in the AIEOP-BFM acute lymphoblastic leukemia 2009 Study. Ther Drug Monit. 2020;42(3):435–444. doi:10.1097/FTD.0000000000000727
   PubMed Web of Science ®Google Scholar
• Mondelaers V, Ferster A, Uyttebroeck A, et al. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-hodgkin lymphoma in Belgium. Br J Haematol. 2020;190(1):105–114. doi:10.1111/bjh.16495
   PubMed Web of Science ®Google Scholar
• Yang Q, Jacobs TM, McCallen JD, et al. Analysis of pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the general population. Anal Chem. 2016;88(23):11804–11812. doi:10.1021/acs.analchem.6b03437
   PubMed Web of Science ®Google Scholar
• Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group. Blood. 2013;122(4):507–514. doi:10.1182/blood-2013-01-480822
   PubMed Web of Science ®Google Scholar
• Verma A, Chen K, Bender C, Gorney N, Leonard W, Barnette P. PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability. Pediatr Hematol Oncol. 2019;36(5):277–286. doi:10.1080/08880018.2019.1634778
   PubMed Web of Science ®Google Scholar
• August KJ, Farooki S, Fulbright JM, et al. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatr Blood Cancer. 2020;67(1):e28021. doi:10.1002/pbc.28021
   PubMed Web of Science ®Google Scholar
• Marini BL, Brown J, Benitez L, et al. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma. 2019;60(12):2854–2868. doi:10.1080/10428194.2019.1608530
   PubMed Web of Science ®Google Scholar
• Raja RA, Schmiegelow K, Frandsen TL. Asparaginase-associated pancreatitis in children. Br J Haematol. 2012;159(1):18–27. doi:10.1111/bjh.12016
   PubMed Web of Science ®Google Scholar
• Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol. 2000;34(3):200–205. doi:10.1002/(sici)1096-911x(200003)34:3<200::aid-mpo7>3.0.co;2-t
   PubMedGoogle Scholar
• Flores-Calderón J, Exiga-Gonzaléz E, Morán-Villota S, Martín-Trejo J, Yamamoto-Nagano A. Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase. J Pediatr Hematol Oncol. 2009;31(10):790–793. doi:10.1097/MPH.0b013e3181b794e8
   Web of Science ®Google Scholar
• Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2007;49(5):634–639. doi:10.1002/pbc.21037
   PubMed Web of Science ®Google Scholar
• Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009;53(2):162–167. doi:10.1002/pbc.22076
   PubMed Web of Science ®Google Scholar
• Samarasinghe S, Dhir S, Slack J, et al. Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2013;162(5):710–713. doi:10.1111/bjh.12407
   PubMed Web of Science ®Google Scholar
• Rank CU, Wolthers BO, Grell K, et al. Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age. J Clin Oncol. 2020;38(2):145–154. doi:10.1200/JCO.19.02208
   PubMed Web of Science ®Google Scholar
• Wolthers BO, Frandsen TL, Baruchel A, et al. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017;18(9):1238–1248. doi:10.1016/S1470-2045(17)30424-2
   PubMed Web of Science ®Google Scholar
• Carpentieri U, Balch MT. Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors. J Pediatr. 1978;93(5):775–778. doi:10.1016/s0022-3476(78)81075-0
   Web of Science ®Google Scholar
• Khan A, Adachi M, Hill JM. Potentiation of diabetogenic effect of L-asparaginase by prednisolone. Horm Metab Res. 1970;2(5):275–276. doi:10.1055/s-0028-1095058
   Google Scholar
• Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf. 1996;15(2):135–157. doi:10.2165/00002018-199615020-00005
   Web of Science ®Google Scholar
• Salzer WL, Devidas M, Shuster JJ, et al. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol. 2007;29(6):369–375. doi:10.1097/MPH.0b013e3180640d54
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–2253. doi:10.3109/10428194.2011.596963
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Darbandi R, Pei D, et al. Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer. 2014;50(15):2685–2694. doi:10.1016/j.ejca.2014.06.023
   PubMed Web of Science ®Google Scholar
• Parsons SK, Skapek SX, Neufeld EJ, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 1997;89(6):1886–1895. doi:10.1182/blood.V89.6.1886
   PubMed Web of Science ®Google Scholar
• Finch ER, Smith CA, Yang W, et al. Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(1):e28040. doi:10.1002/pbc.28040
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, de Groot-kruseman HA, et al. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. Haematologica. 2014;99(11):1716–1721. doi:10.3324/haematol.2014.109413
   PubMed Web of Science ®Google Scholar
• Cohen H, Bielorai B, Harats D, Toren A, Pinhas-Hamiel O. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54(5):703–706. doi:10.1002/pbc.22305
   PubMed Web of Science ®Google Scholar
• Zawitkowska J, Lejman M, Zaucha-Prażmo A, Sekuła N, Greczkowska-Chmiel T, Drabko K. Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia. Transfus Apher Sci. 2019;58(5):634–637. doi:10.1016/j.transci.2019.08.025
   Web of Science ®Google Scholar
• Sahoo S, Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis. 2003;23(3):295–299. doi:10.1055/s-2003-42647
   PubMed Web of Science ®Google Scholar
• Toksvang LN, De Pietri S, Nielsen SN, et al. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. Pediatr Blood Cancer. 2017;64(9). doi:10.1002/pbc.26519
   Web of Science ®Google Scholar
• Kloos RQH, Pieters R, van den Bos C, van Eijkelenburg NKA, de Jonge R, van der Sluis IM. The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(12):3002–3010. doi:10.1080/10428194.2019.1613537
   PubMed Web of Science ®Google Scholar
• Schulte RR, Madiwale MV, Flower A, et al. Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. Leuk Lymphoma. 2018;59(10):2360–2368. doi:10.1080/10428194.2018.1435873
   PubMed Web of Science ®Google Scholar
• Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res. 2000;24(7):559–565. doi:10.1016/s0145-2126(00)00017-5
   PubMed Web of Science ®Google Scholar
• Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216–2222. doi:10.1182/blood-2006-04-015511
   PubMed Web of Science ®Google Scholar
• Nowak-Göttl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol. 2009;22(1):103–114. doi:10.1016/j.beha.2009.01.003
   Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452–459. doi:10.1111/j.1365-2141.2010.08524.x
   PubMed Web of Science ®Google Scholar
• Klaassen ILM, Lauw MN, Fiocco M, et al. Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: risk factors and effect on prognosis. Res Pract Thromb Haemost. 2019;3(2):234–241. doi:10.1002/rth2.12182
   PubMed Web of Science ®Google Scholar
• Mogensen SS, Harila-Saari A, Mäkitie O, et al. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(10):e27300. doi:10.1002/pbc.27300
   PubMed Web of Science ®Google Scholar
• Patel B, Richards SM, Rowe JM, Goldstone AH, Fielding AK. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia. 2008;22(2):308–312. doi:10.1038/sj.leu.2405032
   Web of Science ®Google Scholar
• Liu C, Janke LJ, Kawedia JD, et al. Asparaginase potentiates glucocorticoid-induced osteonecrosis in a mouse model. PLoS One. 2016;11(3):e0151433. doi:10.1371/journal.pone.0151433
   Web of Science ®Google Scholar
• Te Winkel ML, Appel IM, Pieters R, van den Heuvel-eibrink MM. Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia. Haematologica. 2008;93(10):1570–1574. doi:10.3324/haematol.12956
   Web of Science ®Google Scholar
• Liu C, Kawedia J, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26(11):2303–2309. doi:10.1038/leu.2012.102
   PubMed Web of Science ®Google Scholar
• Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent versus continuous PEG-Asparaginase to reduce Asparaginase-associated toxicities: a NOPHO ALL2008 Randomized Study. J Clin Oncol. 2019;37(19):1638–1646. doi:10.1200/jco.18.01877
   Web of Science ®Google Scholar
• Mogensen SS, Schmiegelow K, Grell K, et al. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017;102(5):e175–e178. doi:10.3324/haematol.2016.160507
   PubMed Web of Science ®Google Scholar
• Mattano LA, Devidas M, Friedmann AM, et al. Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): a report from the Children’s Oncology Group (COG) study AALL0331. J Clin Oncol. 2013;31(15_suppl):10002. doi:10.1200/jco.2013.31.15_suppl.10002
   Web of Science ®Google Scholar